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1INTRODUCTION
Hirsutism is defined as the presence of terminal coarse hairs in
women in a male like distribution. Hirsutism affects approximately 5 to
10% of women of reproductive age.1 Androgen dependent areas include
the chin, upper lip, chest, abdomen, back and anterior thighs.
           Hirsutism usually represents a variation of normal hair growth, but
rarely it is a harbinger of a serious underlying condition. It may be a
complaint for which the patient seeks medical advice or may be only a
suspicion by a dermatologist seeing a woman for other androgen related
problems like female pattern hair loss. Studies of the psychological
burden of hirsutism suggest that it has a significant impact and adversely
affects quality of life.2
  Virilisation refers to a condition in which androgen levels are
sufficiently high to cause additional signs and symptoms such as
deepening of voice, breast atrophy, increased muscle bulk, clitoromegaly
and increased libido. Virilisation is an ominous sign that suggests the
possibility of an ovarian or adrenal neoplasm. Genetic factors and ethnic
background also influence hair growth. In general, dark haired
individuals tend to be more hirsute than fair individuals.
2REVIEW OF LITERATURE
Perception of hirsutism is by definition subjective and women
present with a wide variation in severity.(3,4) Both the severity of the
hirsutism and the degree of its acceptance are dependant on racial,
cultural and social factors.
Influence of hormone on hair development:
Growth of sexual hair is dependant on sex hormones, which can act
on the dermal papilla to convert small, straight, non pigmented vellus hair
into coarse, pigmented terminal hair. It increases the duration of the
anagen phase of the hair growth cycle in the beard, axillary and pubic
areas. Conversely, androgens can also have the opposite effect on specific
scalp areas often in the same individual, causing balding. This involves a
reverse transformation of large, terminal, heavily pigmented scalp hairs to
miniaturized vellus follicles resulting in androgenetic alopecia. These
contrasts must be due to intrinsic differences in gene expression within
follicles at different sites.
          In the skin, testosterone is converted to the more potent
dihydrotestosterone (DHT) by the enzyme 5alpha reductase.5 There are
two isoenzymes of 5alpha reductase: type 2 is found in the prostate gland
3and in hair follicle whereas type 1 is found primarily in sebaceous
glands.6
In non androgen dependent areas such as the forehead and cheeks,
androgens enlarge the sebaceous glands; however hair follicles remain
vellus in nature. Hair growth on the chest, upper abdomen and back
requires greater levels of androgens and is therefore more characteristic
of the pattern typically seen in males.
In men, over 95% of testosterone originates from the Leydig cells
of  testes.  In women, 40-50% of testosterone arises from the ovaries and
adrenals while the remaining 50-60% comes from peripheral conversion
of androstenedione which arises from both ovaries and adrenal glands. It
can either be converted to estrogen by the enzyme aromatase in granulosa
cell or to testosterone by the enzyme 17beta hydroxysteroid
dehydrogenase in theca cell. In both genders, dihydroxytestosterone
arises from peripheral conversion of dehydroepiandrosterone sulphate.
Pathogenesis of Hirsutism:
Hirsutism results from either an exogenous or endogenous increase
in circulating androgens or from increased sensitivity of the hair follicle
to normal serum androgen levels (end organ dysfunction). Although
4androgen excess underlies most cases of hirsutism, the clinical severity of
hirsutism does not always correlate with the expected levels of circulating
androgens. There is considerable heterogeneity of responses among
androgen dependant follicles in different individuals. This is due to
variability in end organ sensitivity.(7,8,9)
          Key androgens that may be secreted in excess include testosterone
which usually originates from the ovary; DHEAS which is of adrenal
origin; and androstenedione which originates from either the ovary or the
adrenal gland.10
Prostate specific antigen measurements have a potential use in
monitoring the treatment of hirsutism in addition to being a marker of
androgen excess.11
Etiologies of Hirsutism:12
1. Constitutional or idiopathic hirsutism
2.  Pituitary or hypophyseal hirsutism
3. Ovarian hirsutism -
? Tumoural: Arrhenoblastomas, hilus cell tumour, granulosa cell
tumour, gonadoblastomas.
? Non tumoural:Polycystic ovarian syndrome, ovarian hyperthecosis.
54. Adrenal hirsutism-
? Tumoural: Virilising adenomas, carcinomas
? Non tumoural : Congenital hyperplasia, Cushings syndrome
5.  Iatrogenic hirsutism
6.  Hepatic hirsutism
7.  Hirsutism due to alteration of peripheral conversion of androgen
Idiopathic Hirsutism:
Androgen excess is not detectable in every patient with hirsutism.
Those patients with hirsutism, regular ovulation, and normal to slightly
elevated androgen levels in the absence of features that suggest other
causes of hirsutism are labeled as having idiopathic hirsutism.(13,14)
Women with this syndrome may also present with seborrhoea, acne and
alopecia (SAHA syndrome). Pathophysiology of idiopathic hirsutism is
related to increased peripheral activity of 5alpha reductase in the hair
follicle, which converts testosterone to the more potent androgen,
dihydrotestosterone(DHT). Gonadotropin releasing hormone (GnRH)
analogue and ACTH stimulation tests may uncover occult ovarian or
adrenal functional hyperandrogenism in a large number of these patients.
Increased prevalence of insulin resistance and impaired glucose tolerance
has been observed in idiopathic hirsutism.15
6Polycystic ovarian syndrome:
Polycystic ovarian syndrome (PCOS), also known as Stein-
Leventhal syndrome, is the most common cause of hirsutism.16 It  can
present with hyperandrogenism; menstrual irregularities including
oligomenorrhoea, amenorrhoea and infertility; and dysmetabolic
syndrome that includes impaired glucose tolerance, hyperlipidemia and
obesity (Body mass index>30kg/m2).17 Among hirsutes with abnormal
cycles, obese women have higher levels of total testosterone, free
testosterone and androstenedione. These patients are also at increased risk
for cardiovascular disease.18 Polycystic ovaries are not necessary to make
the diagnosis.
Proposed diagnostic criteria for polycystic ovarian syndrome19
(Rotterdam Criteria):
Two of the three criteria necessary for diagnosis  -
1.  Oligo or anovulation (<8menses/year or cycles >35 days)
2.  Clinical and/or biochemical signs of hyperandrogenism
3.  Presence of polycystic ovaries and absence of other etiologies
(Cushing’s syndrome, congenital adrenal hyperplasia, androgen secreting
tumors)
7The gene for PCOS is inherited in an autosomal dominant pattern.
Nearly half of the sisters of PCOS patients have an elevated plasma
testosterone level, of which half of them (about 25% of the total) have
symptomatic PCOS. Male relatives also carry the gene. Significant male
balding  before  the  age  30  years  with  or  without  concomitant  insulin
resistance are suggestive of male PCOS carrier status.20 Women with
polycystic ovaries and their brothers with early balding show links to the
steroid metabolism gene, CYP17.21
The major source of hyperandrogenemia in PCOS appears to be
gonadotropin dependant functional ovarian hyperandrogenism.10 In  a
small  fraction  of  patients  with  PCOS,  elevated  DHEAS  is  found.  The
high intra ovarian androgen concentration causes maturation arrest of
ovarian follicles, which accounts for the “polycystic” appearance of the
ovaries.
Adrenal hirsutism:
Congenital adrenal hyperplasia:
A deficiency of 21? hydroxylase is responsible for 95% of all
cases.22  It  results in defective conversion of 17 hydroxy progesterone to
11 deoxycortisol. There are three clinical forms:12
81. Classic form or salt losing form- relate to failure of aldosterone
synthesis.
2. Non classic form- accompanied by failure of cortisol synthesis.
The absence of cortisol causes hyperproduction of ACTH, which
produces adrenal hyperplasia. Oligomenorrhoea, clitoromegaly,
masculinisation, changes in voice and lack of breast development
are other manifestations.
3. Late onset congenital adrenal hyperplasia - due to partial
deficiency of  21?  hydroxylase which manifests when demand
for steroid increases. Patients often present with premature
pubarche with onset of hirsutism in the prepubertal years.
Menstrual irregularity, oligomenorrhoea or primary amenorrhoea
may also be present.23
Benign and malignant androgen secreting tumours should be
suspected in cases with sudden onset and rapidly progressing hirsutism,
features of virilization (deepened voice, clitoromegaly, increased muscle
mass, increased libido) and significantly elevated androgen level.
9Pituitary hirsutism:
Many of the endocrinopathies are the result of a pituitary adenoma.
Visual field defect can occur due to impingement on the optic chiasma.
Pituitary adenomas result in hyperprolactinemia, acromegaly and
Cushing’s disease and hirsutism. Some of the features include:
- Cushing’s disease :  Hypertension, proximal muscle atrophy, striae,
thinned skin with easy bruising, fat redistribution (moon facies,
dorsocervical fat pad, supraclavicular fat pad, central and less
commonly generalized obesity), hyperpigmentation, cutaneous
fungal and bacterial infections
- Acromegaly: Coarse facies, large hands, acanthosis nigricans
- Thyroid dysfunction: Tremors, brittle hair, diffuse telogen hair
loss, dry skin, goiter
-  Hyperprolactinemia: Spontaneous or expressible galactorrhoea
Drugs causing hirsutism:24
Androgenic medications:
? Testosterone
? Danazol
? ACTH
10
? Metyrapone
? Phenothiazine
Anabolic steroids
Androgenic progestins
? Levonorgestrel
? Norgestrel
? Norethindrone
Acetazolamide
Valproic acid
Nonandrogenic medications
? Cyclosporine
? Phenytoin
? Diazoxide
? Minoxidil
? Minocyclin
? High dose glucocorticoids
? Hexachlorobenzene
? Penicillamine
? Psoralens
11
HAIR - AN syndrome:
Hyperandrogenism, insulin resistance and acanthosis nigricans
(HAIR-AN) syndrome is distinct from PCOS. It tends to have a greater
degree of associated morbidity, like type 2 diabetes, hypertension and
cardiovascular disease. The pathogenesis is thought to be related to an
insulin receptor and/or post receptor defect resulting in the compensatory
increase in circulating insulin and luteinizing hormone. These hormones
stimulate excess ovarian androgen secretion. Associated features include
PCOS, cystic mastitis, obesity, and infertility.25
Hirsutism in postmenopausal:
Hirsutism may be due to a number of causes including tumours. It
may also be due to ovarian hyperthecosis in which ovarian interstitial
cells differentiate into steroidogenically active luteinized stromal cells.
Ovarian estrogen production decreases causing a reduction in
concentration of SHBG. Consequently, there is an increase in the
proportion of unbound testosterone, resulting in hirsutism.
Hirsutism in pregnancy:
It is due to luteoma of pregnancy, hyperreactio luteinalis or
aromatase deficiency in the fetus. The maternal hyperandrogenism
resolves in the postpartum period.
12
Hepatic hirsutism:12
A low level of sex hormone binding globulin (SHBG) leads to a
larger amount of free testosterone and the conversion to dihydroxy
testosterone may be greater. As SHBG is produced in liver, in cases of
liver diseases SHBG level are decreased.
Cutaneous associations:6
? Acne vulgaris
? Androgenetic alopecia
? Acanthosis nigricans
? Skin tag
? Seborrhoea
Metabolic syndrome and hirsutism:
The metabolic syndrome and polycystic ovarian syndrome (PCOS)
are frequently associated with abdominal obesity, dyslipidemia, and
insulin resistance. Both are risk factors for cardiovascular events and
stroke.26 It is thought that hyperinsulinemia may play an important role in
the development of both syndromes.27 Thus, there is considerable overlap
between PCOS and metabolic syndrome patient populations. Hirsutism in
women is an important presenting clinical symptom which often leads to
13
the diagnosis of PCOS. Hence it is important to consider the diagnosis,
implications, and treatment of metabolic syndrome in patients presenting
with hirsutism.28
The International Diabetes Federation (IDF) definition of metabolic
syndrome.
Central obesity : Waist circumference
Men >90cm
Women >80cm
The above plus two of the following four features
Glucose or insulin
abnormalities-
Fasting plasma glucose >100mg/dl
Or previously diagnosed type 2
diabetes
Dyslipidemia - Triglycerides >150mg/dl or specific
treatment for this abnormality
Dyslipidemia - HDL <40 mg/dl (men)
HDL <50 mg/dl (women) or specific
treatment for this abnormality
Elevated blood pressure
-
BP > 130/85 mmHg or treatment of
previously diagnosed hypertension
Clinical assessment:
Assessment of hirsutism includes the age of onset, rate of
progression of hair growth and associated symptoms and signs (e.g.,
acne). Growth is usually slow but progressive. Sudden development and
14
rapid progression of hirsutism suggests the possibility of an androgen
secreting tumour, in which case virilisation may also be present.
The age of onset of menstrual cycle and the pattern of the
menstrual cycle should be noted; irregular cycles from the time of
menarche are more likely to result from ovarian rather than adrenal
androgen excess. Associated symptoms such as galactorrhoea should
prompt evaluation for hyperprolactinemia and hypothyroidism.
Hypertension, striae, easy bruising, centripetal weight gain and weakness
suggest hypercortisolism (Cushing’s syndrome). A family history of
infertility and/or hirsutism may indicate disorders such as non classic
CAH.
Physical examination should include measurement of height,
weight and calculation of body mass index (BMI). A BMI of >25 kg/m2
is indicative of excess weight for height, and values >30kg/m2 are often
seen in association with hirsutism. Notation should be made of blood
pressure, as adrenal cause may be associated with hypertension.
Objective measurement of hirsutism:
An objective clinical assessment of hair distribution and quantity is
central to the evaluation in any woman presenting with hirsutism. This
assessment provides the baseline reference point to gauge the response to
15
treatment. A simple and commonly used method to grade hair growth is
classical or modified Ferriman- Gallway scale where each of nine
androgen sensitive sites is graded from 0 to 4.29 It is normal for most
women to have some hair growth in androgen sensitive areas. Score of 8
or more suggest excess androgen mediated growths.30
1 2 3 4
Upperlip Small number
of terminal
hairs over
outer lip
border
Thin
moustache
covering less
than 50%
Moustache
covering
50% from
margin or
50% the lip
height
Moustache
covering
most of
upper lip &
crossing the
midline
Chin Sparse
terminal hair
on chin
Sparse
terminal hair
with small
thickened
areas
Entire chin
covered
with light
growth
Entire chin
covered
with heavy
growth
Chest Circumareolar
or midline
terminal hair
Circumareolar
and midline
terminal hair
75% of
chest
covered
with
terminal
hairs
Entire area
covered
with
terminal
hair
Abdomen Scattered
midline
terminal hairs
More terminal
hairs, still
midline
50% of
upper
abdomen
covered
Entire area
covered
with
terminal
hair
Pelvis Small number
of scattered
midline
terminal hairs
along the
length of linea
alba
Midline
concentration
of terminal
hair along the
length of linea
alba
A midline
thickened
band of
terminal
hair less
than ½
width of
pubic hair
An inverted
V shaped
coverage ½
width of
pubic at
base
16
Upper
arms
Scattered
terminal hair
over less than
25% of upper
arm
Increased but
incomplete
coverage
Entire area
covered
with light
growth
Entire area
covered
with heavy
growth
Thighs Scattered
terminal hair
over less than
25% of thigh
Increased but
incomplete
coverage
Entire area
covered
with light
growth
Entire area
covered
with heavy
growth
Upper
back
Sparse
terminal hairs
over upper
back
Increased
number of
spread
terminal hairs
Entire area
covered
with light
growth
Entire area
covered
with heavy
growth
Lower
back
Sacral area
with hair
coverage less
than 4 cm
wide
Increased
sides coverage
75% of
lower back
covered
with
terminal
hairs
Entire area
covered
with heavy
growth
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Other methods for measuring hirsutism:24
Hatch and colleagues method: This is also a variation of the
Ferriman Gallwey technique. The lower legs and lower arms were not
included.
Lorenzo’ s study of hirsutism: Its score pattern was based on only
five body regions namely chin, upper lip, chest, abdomen and thighs.
Abraham’ s classification based on Ferriman Gallwey score:12
Score Presentation
<8 Normal
8 – 16 Discrete hirsutism
17 – 25 Moderate hirsutism
>25 Significant hirsutism
18
Hormonal evaluation:31
Total testosterone: Early morning plasma total testosterone
estimation is usually done on days 4 to 10 of the menstrual cycle.16 If it is
more than 200ng/ml, more extensive investigation for virilising tumour to
be done.32
? Free testosterone: The fraction of testosterone that is not bound to its
carrier protein, sex hormone binding globulin, is biologically available
for conversion to DHT and for binding to androgen receptors.
? Sex hormone binding globulin (SHBG): Hyperinsulinemia and/or
androgen excess decreases hepatic production of SHBG, resulting in
elevated levels of unbound testosterone.
? Dehydroepiandrosterone sulphate (DHEAS): It is a supplementary test
if there is raised testosterone. More than 7 microgram/ml suggests an
adrenal tumour.
? LH to FSH ratio: Increased ratio (>2) is suggestive of PCOS.17
? Serum FSH and estradiol levels: Measured in women presenting with
oligo/anovulation to exclude the possibility of hypogonadotropic
hypogonadism (ovarian dysfunction of pituitary origin).
? 17 hydroxy progesterone: Measurement of serum 17-
hydroxyprogesterone is useful to differentiate between late onset
19
congenital adrenal hyperplasia and PCOS. If the early morning 17
hydroxyprogesterone is <200ng/dl or if ACTH stimulated 17 hydroxy
progesterone level is <1000ng/dl, late onset CAH is unlikely to be the
diagnosis.
? Serum prolactin: Evaluated for hyperprolactinemia, but also elevated
in PCOS, acromegaly and thyroid disorders.
?  24-hour urine cortisol:
Urine  cortisol  values  of  greater  than  50  to  100  ?g/dl  in  an  adult
suggest the diagnosis of Cushing’s syndrome. This is considered as the
most specific test.
? Overnight low-dose dexamethasone suppression test:
1 mg of dexamethasone is given at 11 PM, plasma cortisol level at
8 AM  the next morning should be measured. In unaffected individuals,
usually  the  levels  will  be  <  1.8  ?g/dl.  Because  adrenal  androgens  are
readily suppressed by low doses glucocorticoids, the dexamethasone
androgen suppression test  distinguishes ovarian from adrenal androgen
overproduction.
? Thyroid function test: TSH, free T3. Hirsutism has been reported with
congenital hypothyroidism.33
? GnRH analogue & ACTH combined stimulation test:
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100 microgram of GnRH analogue is given subcutaneously.
Patients with subtle hyperandrogenemia are expected to show higher
response of 17 hydroxyprogesterone and total testosterone. ACTH 250
microgram is also administered as intravenous infusion. Again, patients
with occult hyperandrogenemia show increased responses of 17 hydroxy
progesterone, total testosterone and plasma cortisol.
? Somatomedin-C  level: Screened for acromegaly.
? Glucose tolerance test
? Lipid profile
? USG abdomen: Useful to identify ovarian mass
? CT/MRI: Used to localise adrenal mass or pituitary tumour
Serological indices in hirsutism:
Although the testosterone level does not correlate with the severity
of hair growth, it correlates with the complex formula given below:(34,35)
(Testosterone/SHBG) + (Androstenedione/100) +
(Dehydroepiandrosterone sulfate/100)
Index of free testosterone = (100×Total Testosterone)/SHBG
Medical treatment: 36
Oral contraceptives
21
Antiandrogens
? Cyproterone acetate
? Drospirenone
? Spironolactone
? Flutamide
Enzyme inhibitors
? Finasteride
? Eflornithine
Insulin-sensitizing agents
? Metformin
? Rosiglitazone
? Pioglitazone
Gonadotropin releasing hormone analogues
? Leuprolide
? Nafarelin
Adjuvants:
Epilation methods
? Physical and chemical epilation
? Electrolysis or electroepilation
? Laser/photoepilation
22
The medical treatment of hirsutism is used to rectify any causal
hormonal imbalance and improve the aesthetic appearance of hirsutism.
The primary goal is to achieve central or peripheral androgen suppression
using four groups of drugs like androgen production inhibitors (oral
contraceptives, gonadotropin releasing hormone [GnRH] analogues),
peripheral androgen blockers (cyproterone acetate, flutamide, and
spironolactone), enzyme inhibitors (finasteride), and insulin-sensitizing
agents (rosiglitazone, metformin).
Oralcontraceptives:
Combined oral contraceptives containing ethinyl estradiol 20- 35
microgram and one of the newer progestogens (desogesterol &
gestodene) or cyproterone acetate are the most suitable for the treatment
of androgenic symptoms because of their relative non androgenicity. This
less androgenic effect induces a significant increase in SHBG and IGF
binding protein with a resulting reduction of free testosterone.37
Antiandrogens
Cyproterone acetate:
             Cyproterone acetate (CPA) acts mainly by blocking androgen
receptors in target organs, and also reduces the activity of skin 5?-
reductase, the enzyme responsible for converting testosterone to the more
23
potent androgen, dihydrotestosterone. It also suppresses gonadotropin
secretion thereby reducing ovarian and adrenal androgen production.38
The progestin activity of CPA requires the drug to be combined
with estrogens in women. Patients not desiring conception can be given
cyclic cyproterone acetate 2mg/day along with ethinyl estradiol 35
microgram/day for 21 days followed by a 7 days rest. No clinical
differences in outcome were found between cyproterone acetate and the
other medical therapies like ketoconazole, spironolactone, flutamide,
finasteride, and GnRH analogues.39 Cyproterone acetate can lead to liver
function abnormalities, weight gain, loss of libido and menstrual
irregularity.
Spironolactone:
Spironolactone is an aldosterone antagonist and androgen receptor
antagonist, exhibits a dose-dependent competitive inhibition of the
androgen receptor. It also inhibits 5? reductase enzyme.40 Spironolactone
is an effective treatment for androgen-dependant hirsutism in doses
ranging from 50 to 200 mg/day. Spironolactone in combination with
OCPs is more effective than OCPs alone.38
24
Spironolactone can elevate potassium by blocking the effect of
aldosterone on the kidney. Blood pressure and potassium concentrations
should be screened every 4 weeks. Spironolactone should not be used to
treat hirsutism in women with renal insufficiency or hyperkalemia.
Drospirenone:
Drospirenone,  a  progestin  used  in  several  OCPs,  is  also  an
antiandrogen. Drospirenone 3 mg (the dose used in OCPs) is roughly
equivalent to spironolactone 25 mg or CPA 1 mg. It improves the clinical
signs of hirsutism via antiandrogenic and antimineralocorticoid action.41
There is a significant fall in serum total and free testosterone levels with a
concomitant increase of sex-hormone-binding globulin (SHBG).42
Flutamide and bicalutamide:
Flutamide is a nonsteroidal compound that seems to act only at the
androgen receptor site and is therefore considered a pure antiandrogen
agent.  The serum half-life of flutamide is approximately 6 hours.
Flutamide is usually used in dosages ranging from 250 to 750 mg daily.
Liver toxicity is a rare but potentially severe side effect. Serum
transaminases should be measured frequently. Some side effects such as
dry skin, diarrhoea, nausea, and vomiting have also been reported.
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Low-dose bicalutamide 25 mg/day is a new potent orally active
well-tolerated, non steroidal pure antiandrogen with a halflife of 7–10
days. Bicalutamide has been shown to be an effective drug in the
treatment of patients with hirsutism due to PCOS and also in idiopathic
hirsutism with no significant side effects or modifications in menstrual
cycles. Hepatotoxic effects have been reported at doses of 50 mg per day.
Enzyme inhibitors
Finasteride:
Finasteride is an antiandrogen which competitively inhibits type 2
isoenzyme of 5? –reductase.16 Thereby it decreases the amount of
hormone available peripherally for interaction with the androgen receptor
without altering ovarian and adrenal androgen secretion. The serum
halflife of finasteride is 6 to 8 hours. Interestingly a single dose of
finasteride suppresses serum DHT levels for up to 4 days. This
phenomenon is probably due to the high affinity of finasteride towards 5?
reductase enzyme.
Finasteride is used in doses of 1 mg to 5 mg/day. It can lower
hirsutism scores by 30–60% in addition to reducing the average hair
diameter.43 The use of any drug with antiandrogen effect requires a safe
and effective method of contraception in order to avoid the potential risk
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of feminization of a male fetus. Considering the halflife of all mentioned
drugs used in the treatment of hirsutism, it seems to be safe for a woman
to become pregnant after discontinuation of the therapy for 10 days.
Insulin-sensitizing agents
Rosiglitazone and metformin:
Insulin sensitizing agents are metformin, rosiglitazone, and
pioglitazone. They are widely available standard medications for the
treatment of non insulin-dependent diabetes mellitus. When given to non
diabetic subjects, they lower only insulin levels, not blood sugar levels.
           Metformin decreases hepatic glucose production, lowers insulin
levels with improved insulin sensitivity and has an elimination halflife of
about 6 hours. Thiazolidinediones (TZDs) improve the action of insulin
in the liver, skeletal muscle, and adipose tissue. By reducing
hyperinsulinemia, both metformin and TZDs reduce adrenal & ovarian
androgen biosynthesis and raise levels of SHBG44,45 Thereby they reduce
the circulating free & biologically active androgens and ameliorate
hirsutism. In vitro studies demonstrated a direct effect of metformin on
ovarian steroidogenesis.46 When using rosiglitazone and pioglitazone, a
regular monitoring of liver enzyme levels is recommended.44
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Although metformin seems to be safe during pregnancy with no
evidence of teratogenicity, it should be discontinued during pregnancy as
there are no sufficient epidemiological data. Rosiglitazone and
pioglitazone are Class C drugs with evidence of teratogenicity in animals.
They should not be used in women of childbearing age unless they are
strictly combined with an effective method of contraception.
Gonadotropin–releasing hormone (GnRH) analogues:
Leuprolide acetate, a GnRH agonist causes sudden release of
gonadotropins that result in desensitization and downregulation of GnRH
receptors. This leads to suppression of testosterone and estradiol
synthesis. It is used as a rescue medication in patients not responding or
not tolerating OCPs. It is administered as a depot preparation of 7.5mg
intramuscularly monthly along with 25 -50µg transdermal estradiol.7 Side
effects include hot flushes, osteoporosis and atrophic vaginitis.
Hair removal methods:
Hair removal methods include shaving, waxing, sugaring,
threading, use of tweezers, depilatory creams, electrolysis (so called
electroepilation) and laser epilation. The choice of epilation technique
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depends largely on personal preferences, region to epilate, colour of hair
and cost.
Physical and chemical methods: (4,36)
           Shaving is considered as being rapid, effective, simple, and cheap.
The only disadvantage is that shaving has to be repeated daily and
folliculitis frequently develops when hair regrows.
           Electric rotating epilating devices or waxing techniques (cold or
warm waxes) are both based on hair shaft epilation leading to longer
lasting hair-free effects. The procedure must be repeated every 2–6
weeks. The disavantages are pain, inefficient epilation of short hair, skin
irritation and folliculitis.
            Sugaring is a variant of epilation where a mixture of lemon acid
8.0,     sugar 65.0, glucose 15.0, and aqua purificata 100.0 is used.36 After
being intensely mixed, the paste is applied for 0.5 cm thickness on the
area to be epilated and taken off with a rapid movement.
           For chemical depilation the hair is dissolved by separating the
disulfide bonds and the peptides of the hair keratin. The depilatory
creams used today are mostly based on thioglycolates 2–4%. Calcium
salts of the thioglycolates are preferred as they have very low irritating
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effect in form of creams, lotions, or aerosol foams. After a 5 to 15 minute
leave-on time, they are taken off together with the dissolved hair shafts.
Disadvantage of this method is the irritating potential as, not only the hair
keratin but also upper layers of the epidermis is affected. This method is
preferably used on the legs and should be avoided in skin folds.
           Bleaching of hair helps to make excessive hair less visible. For
home use, 12% hydrogen peroxide preparations as aqueous solutions are
used, which are mixed just before usage together with ammonia-based
solutions or creams and applied for 30 minutes. For any bleaching or
chemical depilation, a small test area should be done first. Disadvantages
of bleaching are irritation and sensitization potential of peroxide/sulfates
which are part of most commercial products. Bleaching is suited for
upper lip, chin, and arms.
Eflornithine:
Eflornithine is the first topical drug for the treatment of unwanted
facial and chin hair. It slows hair growth. The cells in the hair follicle
undergo rapid growth and maturation as they transform into hairs.
Polyamines are needed for this rapid cell growth and differentiation. The
production of these polyamines depends on the activity of an enzyme,
ornithine decarboxylase (ODC). Eflornithine is an irreversible inhibitor of
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ornithine decarboxylase 32 and thereby slow the growth and
differentiation of the cells within the hair follicles. It delays the initiation
of anagen and keeps hair in telogen.
A topical preparation, Eflornithine hydrochloride cream 13.9% is
approved for the treatment of unwanted facial hair in women. Systemic
absorption is extremely low. The common side effects seen with
eflornithine are acne, erythema, pseudofolliculitis barbae, headache , skin
itching, burning or tingling, rash, and ingrown hairs.6 Less common side
effects are swollen lips, nausea, numbness, contact dermatitis, and herpes
simplex.47 Eflornithine was approved by the FDA in July 2000. Facial hair
thinning occurs usually after two months.48
Electrolysis – electroepilation:
           Electrolysis is a technique that can lead to permanent destruction
of the hair follicles. An electric current is delivered by a probe placed in
contact with the hair. An epilation probe is directly introduced in the hair
follicle opening. It damages the hair follicle either by direct current
(galvanic electrolysis) or by high frequency alternating current
(thermolysis); the latter destroys the hair follicle by heat. The “Blend
method” combines both types of these currents and is considered as the
most effective technique for electrolysis.
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           Per session about 100 hair follicles can be treated. Potential
disadvantages are pain, follicular hyperpigmentation, scarring and
sometimes infection. The best results were obtained when electroepilation
was combined with medical treatment to resolve any androgen excess.
Although permanent hair removal can be achieved in some cases, the
success of the technique ultimately relies on the skill of the operator.49
Laser hair removal:
Lasers cause permanent hair reduction rather than permanent hair
removal as wrongly claimed.50 It is defined as a noticeable reduction in
the number of terminal hairs. Laser treatment usually produces complete
but temporary hair loss for 1-3 months followed by partitial but
permanent hair loss. There is noticeable reduction in  the number of
growing hair. Also, regrowing hairs are thinner and  lighter in colour  due
to miniaturization of hair follicles.51
History:
Goldman and colleagues first described the injury of pigmented
hair follicles by  ruby laser in 1963. Subsequently Oshiro and Maruyama
noted hair loss after treatment of naevi with ruby lasers. The possibility of
selectively destroying hair follicles without causing extensive epidermal
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damage was suggested with the introduction of the concept of selective
photothermolysis (Anderson and Parrish 1983). Grossman and colleagues
reported the first clinical controlled study of laser hair reduction in 1996
using ruby laser.
Hair biology: Considerations for laser hair removal:52,53
? For effective long term hair removal,  laser should damage the
main structures responsible for hair growth – bulb and the stem
cells.
? Melanin, the key target chromophore is present in the hairbulb.
? Melanisation occurs only during the anagen phase and hence only
hairs in anagen phase are susceptible.
? Darker the hair colour, more is the melanisation and hence larger is
the quantum of target chromophore available for effective laser
hair removal.
? Thicker the hair, larger is the hairbulb and follicle area. This results
in longer thermal relaxation time requiring longer pulse duration.
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LASER physics:54,55
Physical properties of laser light:
? Laser light is formed of monochromatic photons (light from a
given source is of single wavelength).
? Laser light is coherent (all the photons from laser source are
emitted with the same wavelength, travel in the same direction and
in the same phase).
? Laser light is collimated (laser beam has a constant cross sectional
diameter).
? Laser light has high intensity which is required for transmission of
maximum energy.
? Laser light can be delivered in pulse mode.
? Spot size of the laser beam determines its depth of penetration.
Parameters of laser light:
The interaction of laser energy with the tissue depends on a number
of factors including power, spot size, duration of exposure, wavelength
and tissue properties.
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? Energy that is contained in the light is expressed in joules.
? Fluence or energy density is the actual amount of energy applied to
the unit area of  target tissue. It is expressed as joules/cm2.
? The wavelength of laser light gives its characteristic colour.
? Pulse duration is the amount of time laser energy is applied
(ns,ms).
? Pulse frequency is measured in hertz. It is the repetition rate of
pulse.
? The laser light is delivered in two broad categories: continuous
wave or pulse wave.
In the continuous wave mode, there is an uninterrupted beam of
radiation of relatively low power.
In the pulse mode, the continuous beam can be interrupted to form
pulses.  This  is  achieved  by  cutting  the  beam  either  with  simple
mechanical shutters, mode locking or by Quality switching. Superpulsed
and ultrapulsed lasers produce higher peak power with lesser pulse
durations.
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Laser - Tissue interactions:56
A variety of interactions occur with exposure of the skin to laser
light. The light may either be reflected back from the skin surface,
scattered within the tissue, transmitted through the tissue, absorbed by the
tissue or there can be combination of these effects. The absorption of
laser energy results in its conversion to thermal energy. There are three
means by which light can cause follicular damage: photothermal,
photomechanical, or photochemical. Photothermal injury is the principal
mechanism of action for most currently available lasers.
Selective photothermolysis:57
The tendency of chromophores to absorb energy is wavelength
dependent.
          The theory of selective photothermolysis postulates that light of a
wavelength which is absorbed by a target chromophore will selectively
damage or destroy that chromophore if the fluence is sufficiently high
and the pulse duration is less than or equal to the thermal relaxation time
of  that  chromophore.  If  the  pulse  duration  is  less  than  the  thermal
relaxation time, heat diffusion does not take place and damage is
selectively confined to the target.
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The concept of selective photothermolysis has been successfully
used in laser hair removal. Melanin is the target chromophore in the hair
for selective photothermolysis. The therapeutic window of wavelength
for melanin is between 630 – 1100 nm. However, melanin in the
epidermis presents a highly competent site for absoption. Selective
cooling of the epidermis is found to minimize the epidermal damage.58
Various cooling agents and systems such as ice pack, layer of cool gel,
cooled glass chambers, cooled sapphire tip, pulsed cryogen spray and
cold air  are used to effectively cool the epidermis.
Available hair removal systems:59
Laser hair removal systems are grouped into three categories,
depending on their wavelength and type of light source:
1. Red light lasers (Ruby laser - 694nm)
2. Infra red lasers (Alexandrite laser - 755nm; Diode laser - 800nm,
Nd : YAG laser - 1064nm)
3. Intense – pulsed light (IPL) source (550-1200nm) with appropriate
filters 60
All systems are able to temporarily interrupt hair growth, however,
permanent reduction of hair density is mainly based on the number of
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sessions,  fluence  and  intensity  of  the  hair  color.  Blond,  red  and  white
hairs are not suited for laser epilation, whereas dark hair on fair skin is
the optimal target. Often, regrowing hairs are finer and lighter and a
certain reduction is achieved for every session. Depending on the
different published studies this can vary between 10–40%.
Q switched  Nd YAG laser:
It delivers pulses in the nanosecond domain and  is used for hair
removal  on  all  skin  types.  The  Nd  YAG  laser  has  been  proposed  as  an
effective method of hair removal for several reasons. Firstly, its longer
wavelength (1064 nm) allows for better skin penetration of the energy.
Secondly, the Nd YAG laser with a wave length of 1064nm is relatively
less absorbed by cutaneous chromophores. Finally it can treat a large
amount of skin surface quickly.
The reduced melanin absorption at this wavelength necessitates the
need for high fluences in order to adequately damage hair. However, the
poor melanin absorption at this wavelength coupled with epidermal
cooling device makes the Nd YAG laser a safer laser treatment for darker
skin types up to phenotype VI.
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Intense pulsed light:
Intense pulsed, non laser light sources, emitting non coherent,
multi wavelength light have also been used for hair removal. By placing
appropriate filters on the light source, wavelengths ranging from 590 to
1200 nm can be generated. Cut-off filters are used to eliminate short
wavelengths, so that only the longer, more deeply penetrating
wavelengths are emitted. Pulse durations vary in the millisecond domain.
A single or multiple pulse (2-5), with various pulse delay intervals, can be
chosen. The wide choice of wavelengths, pulse duration and delay
intervals make the device potentially effective for a wide range of skin
types.
Recently, IPL systems have been developed that are combined with
1064 nm laser light. These devices should allow for treatment of a wide
spectrum of hair and skin colours.
Exogenous chromophore:
 In persons with blonde, gray or white hair, endogenous
chromophore, melanin, is deficient or absent and effective permanent
laser removal cannot be achieved. For them rather than targeting
endogenous melanin, an exogenous chromophore can be introduced into
the hair follicle and then irradiated with light of a wavelength that
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matches its absorption peak. The main problem is reliable penetration of
the chromophore into all depths of the hair follicle. Therefore the
technique in its present form is apparently inadequate for inducing
permanent hair loss.
Contraindications:
? Superficial cuts/injuries
? Active infections
? Keloidal tendency
? Patients with unrealistic expectations
Side effects:
? Pain & discomfort
? Epidermal damage (vesiculation, crusting)
? Pigmentary alteration- de/hypo/hyper pigmentation
? Textural damage
? Local infection
? Scarring
? Allergy to topical anesthetic creams rarely,  livedo reticularis,
intense pruritus and urticaria.61
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Patient selection:
? The best candidates for laser hair removal are individuals with
black or brown hair.
? People with pale skin, with less melanin chromophore, are better
candidates because the wavelength of laser energy used to destroy
hair follicles is also readily absorbed by the epidermal melanin.
Pre procedure workup:
? A prior detailed history regarding presence of other medical
problem (herpes labialis) or medications that contribute to the
excessive hair growth, history of hypertrophic scars and keloids,
history of any photosensitizing medication or isotretinoin intake
within 1 year should be taken.
? Complete hormonal workup is necessary.
? 4-6 weeks prior to laser, sunscreens can be prescribed.
Hydroquinone can be used in patients with dark skin.
? It is important to explain the patient that this is only hair reduction
and not a permanent hair removal. The outcome and side effects
must be explained at the same time.
? An informed consent is obtained. Photographs can be taken for
records.
41
Procedure:
? Area to be treated is cleaned.
? Topical or local anesthesia is generally used on more sensitive
areas.
? Depending on the equipment, cooling of the epidermis is achieved
with a cooling gel applied before the delivery of a laser pulse.
? Ideal treatment parameters must be individualized for each patient.
? Hand piece is placed perpendicularly to the skin surface and is
either held gently or pressed firmly depending on the laser
systems.
? Laser pulses are placed adjacent to each other with minimal
overlap.
? The normal immediate response is vapourisation of hair shaft
followed, after a few minutes, by perifollicular edema and
erythema.
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Post procedure management:
? Ice packs are given to reduce postoperative pain / swelling.
? A topical antibiotic/steroid combination ointment is given.
? Patient is instructed to avoid sun exposure.
Schedule:
              Repeated treatment is usually given when the hairs start to
regrow (in general 4-6 weeks). Multiple sessions are required to achieve
desired satisfactory results.
Advantages:
? Fewer sessions than electrolysis62 / waxing.
? 50-60% permanency with prolonged hair removal.
? Less discomfort.
? Large areas can be treated in one session.
? Faster results.
? Fewer side effects.
? Better patient compliance.
Disadvantages:
? Expensive.
? Not effective for grey / white hair.
? Multiple treatment sessions
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AIMS OF THE STUDY
? To know the prevalence of hirsutism among different age groups
? To identify the associated factors like acne, acanthosis nigricans,
diabetes mellitus, hypertension and obesity
?  To study the etiology of hirsutism
?  To study the efficacy of Nd YAG laser & IPL in selected
hirsutism patients
? To study the incidence of side effects following Nd YAG laser &
IPL
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MATERIALS AND METHODS
Study design : Prospective descriptive study
Study centre :   Department of Dermatology,
Rajiv Gandhi Government Hospital,
Chennai
Study period :  October 2009 to September 2011.
Sample size : Seventy three patients.
Inclusion criteria : All hirsutism patients with Ferriman
Gallway score of 8 or more.
Exclusion criteria :  Patients with Ferriman Gallway score
of <8.
Clinical evaluation:
Complete history, general examination and dermatological
examination were done for all patients included in the study by using a
proforma. Investigations including postprandial blood glucose, lipid
profile, USG abdomen & pelvis, hormonal assay - LH, FSH, testosterone,
thyroid function test & prolactin were done for all patients. DHEAS & 17
hydroxy progesterone were done for indicated cases. With the
investigation results, endocrine opinion was obtained for all patients.
Polycystic ovarian disease was diagnosed based on Rotterdam Consesus
Criteria.
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Treatment protocol:
For all polycystic ovarian disease patients, Tab.Metformin 500mg
half tablet at bed time was started by endocrinologist. The dose was
gradually stepped up to half tablet twice a day or one tablet twice a day
depending upon the regularity of the patient’s menstrual cycle.
Patients who gave willingness for hair removal procedure were
randomly allotted for Q switched Nd YAG laser and IPL. Those patients
with keloidal tendency, systemic associations, grey hair and pregnancy
were excluded. Duration of treatment, potential adverse effects and post
treatment care were explained to the patients. Written consent was
obtained. Treatment parameters in respect to pulse duration and fluence
were determined according to manufacturer’s recommendation. One cm
square area grid on the treatment site was used to count hair at baseline
and at subsequent intervals (0, 4, 8, 12, 20, 24 weeks). Hair over the
treatment site was shaved on the day of procedure. Digital photographs
were taken before each treatment session.
               Nd YAG laser started from energy level 25%, frequency
2, increased in each sitting by 5%. Pulse duration was 20ns. Treatment
was given for 6 sittings at a gap of 4 weeks.
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              For IPL laser, cooling gel was applied over the area before the
procedure. Fluence started from 10 J/cm2, was slowly increased by
5 J/cm2 for each sitting. Pulse duration was maintained at 5 ms.
Treatment was given for 6 sittings at an interval of 4 weeks.
The study was approved by the institute ethical committee. After
the procedure, patients were advised to avoid sun exposure and physical
sun screen was prescribed. Hair removal efficiency was calculated as a
percentage of the reduction in the number of hairs at each visit compared
with baseline count and was graded as mild (0 – 25%), moderate
(26 – 50%), good (51 – 75%) and excellent (76 - 100%). All the patients
were asked to grade their satisfaction level after the procedure as not
satisfied, satisfied and very satisfied.
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OBSERVATIONS
A total of 73 patients were included in the study.
Table 1 : Age distribution of the study population
Age group (years) Frequency Percentage
15 – 25 32 43.8
26 – 35 21 28.8
36 – 45 17 23.3
46 or more 3 4.1
Total 73 100.0
Most  of  the patients  were in the age group of 15 to 35 years.  The
youngest patient was 15 years old and the oldest patient was 48 years old.
Mean age of patients seen in our study population was 29.19 years.
Table 2 : Age of onset
Age group (years) Frequency   Percentage
<15 19 26.1
16 – 20 19 26.1
21 – 25 17 23.3
26 – 30 11 15
31 – 35 5 6.8
36 – 40 2 2.7
Total 73 100
More  than  50% of  patients  developed  hirsutism before  the  age  of
20 years.
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Duration of the disease varied from 1 to 21 years.
Table 3 : Menstrual status of patients
H/o Menstrual irregularities Frequency Percentage
Yes 35 48%
No 38 52%
       Menstrual irregularities due to various causes like PCOD, Cushing’s
disease, hypothyroidism and congenital adrenal hyperplasia were seen in
35 patients (48%).
Table 4 : Family history association
Family History Frequency Percentage
No 57 78.1
Yes 16 21.9
Around 22% of patients had  positive family history of hirsutism.
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Table 5 : Associations
Associations Frequency Percentage
Acne 13 17.8
Acanthosis nigricans 23 31.5
Androgenetic alopecia 11 15
Infertility 5 12.2(among married)
Most commonly associated cutaneous finding in our hirsutism
patients was acanthosis nigricans (31.5%). Infertility was seen in 12.2%
of married people.
Table 6 : Co-morbidities
Frequency Percentage
 DM /HT 7 9.6
Lipid
abnormalities
8 11
Recently hirsutism is considered as one of the markers of metabolic
syndrome. So, all our patients were screened for diabetes mellitus,
hypertension and lipid abnormalities. Features of metabolic syndrome
were seen in 9.6% of patients. Among 7 patients with diabetes mellitus,
4 patients were above 40 years of age and 3 patients were below 40 years.
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Table 7 : BMI association
BMI Group Frequency Percentage
Normal (18.5 – 24.9) 24 32.9
Excess wt. (25 – 29.9) 27 37.0
Obesity (30 – 39.9) 20 27.4
Morbid obesity (> 40) 2 2.7
Most of the patients in the study population (67%) were above the
normal BMI range. Obesity was seen in 30% of patients. Mean BMI
was 27.
Table 8: Etiological distribution
Etiology Frequency Percentage
PCOS 23 31.5
Hypothyroidism 7 9.6
Idiopathic 38 52.0
Drug 3 4.1
CAH 1 1.4
Cushing’s syndrome 1 1.4
Total 73 100
In our study, more than 50% patients were idiopathic. The next
common cause was PCOS.
A patient with idiopathic hirsutism
A patient with polycystic ovarian disease
USG pelvis showing PCOS
Hirsutism in a hypothyroid patient
Steroid induced hirsutism in a Pemphigus vulgaris patient
Cyclosporine induced hirsutism in a post renaltransplant patient
Hirsutism in cushing’s syndrome
Hirsutism in a congenital adrenal hyperplasia patient
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Table 9 : Ferriman Gallway Scoring
(Abraham’s classification)
FG Score Frequency Percentage
Discrete (8 - 16) 53 72.6
Moderate (17 - 25) 20 27.4
Total 73 100.0
About 73% of patients had Ferriman Galway scoring  (FG score) in
the range of 8 to 16.  The minimum score was 9 and the maximum score
was  21.  The  maximum  score  was  seen  in  a  patient  with  congenital
adrenal hyperplasia. Average FG score was 15.
Of  the  73  patients,  40  patients  were  willing  for  hair  removal
procedure. They were randomly divided into two groups. The first group
received Q switched Nd YAG laser. Second group was treated with IPL.
We could not compare these two groups because of  the small sample size
and  the unequal number of PCOS patients in  the two groups.
Clinical evaluation:
           Among the 23 cases of PCOS (diagnosed based on Rotterdam
criteria), serum testosterone was elevated in 10 patients (43.4%). One
PCOS patient had elevated prolactin level. LH, FSH ratio was more than
2 in 12 patients (52.1%). Polycystic ovaries were seen on pelvic
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ultrasonogram in in 20 patients (86.9%) and DHEAS was elevated only in
5 patients (21.7%).
           Among the total 73 patients. 7 patients had low T4 level and high
TSH level. One patient had elevated 17 hydroxyprogesterone (350ng).
Plasma cortisol level was elevated in one patient which on
dexamethasone suppression, became normal.
Q Switched Nd YAG Group:
Table 10 : Age distribution in Nd YAG Group
Age group Frequency Percentage
18 – 25 13 65.0
26 – 35 5 25.0
36 – 45 2 10.0
    Large number of patients (65%) were below 25 years and were
worried about their physical appearance.
Table 11 : Occupations of  the study patients
Occupation Frequency Percentage
Working 5 25.0
House wife 4 20.0
Student 11 55.0
                         Majority of patients (55%) were students.
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Table 12: Associated factors
Frequency Percentage
PCOS 6 30
Non PCOS 14 70
In the Q switched Nd YAG group, 6 patients had polycystic
ovarian syndrome, all of them on T.Metformin. No other drug was given.
Table 13 : Skin types of study patients
Skin type Frequency Percentage
3 2 10.0
4 10 50.0
5 8 40.0
All the willing patients were randomly included in the study
irrespective of their skin type.
                     Table 14: Areas of treatment in study patients
Site No. ofpatients Percentage
Upper lip 8 40.0
Upper lip & chin 5 25.0
Upper lip, chin & sides 3 15.0
Chin & sides 4 20.0
In this study, all the patients had hair growth over the face. Upper
lip was the commonest site involved.
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Table 15 : Hair removal efficiency (HRE) in Nd YAG group
Degree of  improvement No. of patients Percentage
Mild (0-25%) 0 0
Moderate (26-50%) 2 10
Good (51-75%) 14 70
Excellent (75-100%) 4 20
          In the Q switched Nd YAG group, 70% of study patients had a
good response, 20% of patients had an excellent response and 10% of
patients showed only moderate response.
Table 16 : Treatment sessions required for
good response in NdYAG group
No. of sessions No. of patients Percentage
4 3 16.7
5 12 66.6
6 3 16.7
In all our patients, maximum hair removal was seen after 5 sittings.
This is statistically significant. Energy level used in the 5th sitting  was
45%.
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Table 17: Oneway ANOVA to find the maximum
improvement between sittings in NdYAG Group.
Sittings No. ofpatients
Mean
HRE S.D P value
3 20 44.60 11.596
<0.001
4 20 56.10 7.847
5 20 64.30 8.467
6 20 65.05 8.787
Table 18: Mean HRE in different skin types
of the Nd YAG group.
Skin type No. ofpatients Mean HRE S.D
P value
3 2 72% 8.485
0.3924 10 65.7% 8.944
5 8 62.5% 8.635
Hair removal efficiency of Nd YAG laser was almost equal in the
different skin types of our study patients.
Table 19: Independent samples t-test to compare the mean
improvement between PCOS and non PCOS patients
in NdYAG group.
N Mean HRE S.D P value
Without PCOS 14 64.14 9.256
0.496With PCOS 6 67.16 7.935
There was no difference in hair removal efficacy between PCOS
and non PCOS patients.
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Table 20 : Patient satisfaction for hair removal
Satisfaction levels No. of patients Percentage
Not satisfied 2 10
Satisfied 8 40
Very satisfied 10 50
Half  of  the study patients were very much satisfied with Nd YAG
Laser. They felt that their facial appearance improved.
Table 21: Side effects seen in Nd YAG group
Side effect No. of patients Percentage
Transient erythema 18 90%
Perifollicular edema 18 90%
Pain 16 80%
Crusting 2 10%
Pigmentary disturbances 0 0
Scarring 0 0
In  the  Q  switched  Nd  YAG  group,  90%  of  patients  showed
erythema and edema immediately after laser procedure which resolved
spontaneously in 4-6 hrs. Crusting was seen in 10% of patients in the post
procedure period.
Follow-up:
After 6 months, 10 patients came for follow up. Among them, one
patient had hair regrowth of 30 - 40% and 9 patients maintained their
results.
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IPL Group:
Table 22 : Age distribution in the IPL study Group
Age group Frequency Percentage
18 - 25 9 45.0
26 - 35 6 30.0
36 - 45 5 25.0
       Here also, most of the patients were less than thirty five years of age.
Table 23 : Occupations of study patients in the IPL group
Occupation Frequency Percentage
Working 8 40.0
House wife 6 30.0
Student 6 30.0
Here all the patients’ occupations were almost equally distributed.
Table 24 : Associated factors in the study group
Frequency Percentage
PCOS 11 55
Non PCOS 9 45
All the patients were randomly allotted for laser irrespective of the
associated factors. So in the IPL group, more number of patients had
PCOS. We could not compare the Nd YAG laser & IPL for this reason.
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Table 25 : Skin types of study patients in the IPL group
Skin type Frequency Percentage
3 2 10.0
4 10 50.0
5 8 40.0
Skin types in both groups were equal in number.
Table 26 : Sites of excessive hair growth in IPL group patients
Site No. of patients Percentage
Upper lip 3 15.0
Upper lip  & chin 1 5.0
Upper lip, chin & sides 3 15.0
Chin & sides 13 65.0
In this IPL group, more number of patients had hair growth over
the chin and sides.
Table 27 : Hair removal efficiency (HRE)
in the study population
Degree of improvement Frequency Percentage
Mild 0 0
Moderate 3 15
Good 14 70
Excellent 3 15
Among 20 patients in the IPL group, 70% of patients had good
response and 15% of patients had an excellent response.
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Table 28 : No. of treatment sessions in the study patients
who had good response
No. of sessions No. of patients Percentage
4 9 47.4
5 6 31.6
6 4 21.0
Table 29: One way ANOVA to find the maximum
improvement between sittings in IPL Group.
Sittings N MeanHRE S.D P value
3 20 43.30 11.904
<0.0014 20 53.75 8.932
5 20 50.05 10.154
6 20 60.85 10.236
In the IPL group, most of the patients responded after 4 sittings. On
further sittings, no improvement in response was seen. This is stastically
significant.
Table 30: Mean HRE in different skin types in the IPL group
Skin type No. of patients Mean HRE S.D P value
3 2 67% 12.727
0.6834 10 59.8% 10.559
5 8 60.6% 10.266
Hair removal efficiency of IPL was almost equal in the different
skin types in our study patients.
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Table 31: Independent samples t-test to compare the mean
improvement between PCOS and non PCOS patients
in the IPL Group
N Mean HRE S.D P value
Without PCOS 9 59.67 9.605
0.653With PCOS 11 61.82 11.089
      No difference in hair removal efficacy noted in between PCOS and
non PCOS patients.
Table 32 : Patient satisfaction for hair removal
Satisfaction levels No. of patients Percentage
Not satisfied 1 5
Satisfied 14 70
Very satisfied 5 25
            Among  the 20 patients in the IPL group, 70% of the patients were
satisfied and 25% of the patients were very satisfied with IPL hair
removal.  In the IPL group, no side effects were noted.
           After 6 months, 11 patients came for follow up. Among them, 9
patients maintained their achieved hair removal. But 2 patients developed
regrowth of hair.
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DISCUSSION
         Hirsutism is a frequent reason for cosmetic embarrassment, poor
self esteem and psychological distress for women world over.
               In our study, totally 73 hirsutism patients had been enrolled.
Demographic characters:
Age:
              Our patients’ age group varied between 14 and 48 years. Mean
age was 29.19 years. Most of the patients (72.6%) were in the
reproductive age group (15 to 35 years). This feature is supported by
Nand Lal Sharma et al.63  The  showed  that  mean  age  of  hirsutism  was
25.84  +/_  8.30  years,  50%  of  them  were  in  the  age  group  of   20  -  30
years. Atallah et al64 and QaziMasood Ahmad et al65 also supported this
feature.
             In more than 50% of patients, age of onset of hirsutism was
before 20 years.
             Duration of disease varied from 1 to 21 years.
Menstrual status:
            We noted irregular menstrual cycle in 35 patients (48%) due to
PCOS, Cushing’s disease and hypothyroidism. This correlated with
Tehrani et al who had showed that 54.5% of  their patients had menstrual
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Androgenetic alopecia:
            In this study, 15% of patients had androgenetic alopecia which is
supported by Nand Lal Sharma.63 He  described  16%  of  patients  with
androgenetic alopecia.
Infertility:
    Primary infertility is defined as having the history of trying to
conceive for at least one year without success, despite regular sexual
intercourse, no use of contraception and no previous pregnancy. Among
41 married patients, 5 patients (12.2%) had no children.
Metabolic syndrome:
We had noted 9.6% hirsutism cases with diabetes mellitus and
hypertension. Among 7 patients with diabetes mellitus, 4 patients were
above 40 years of age and 3 patients were below 40 years. Magdalena
Andries showed 6.6% hirsutism cases with diabetes.71
Etiological distribution:
               We have noted that among 73 hirsutism patients, 53% had
idiopathic hirsutism, which was the most common cause found in our
study. Hirsutism with normal ovulatory function and normal circulating
androgen concentrations has been defined as idiopathic hirsutism. PCOS
was seen in 31.5% of patients.  Drugs like cyclosporine and prednisolone
were the cause of hirsutism in 4% of cases and 10% had hypothyroidism.
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Congenital adrenal hyperplasia and Cushing’s disease constitute 1.5%
each. Zargar et al found an incidence of 37.3% PCOS cases in 150
Kashmir patients.72 Qazimasood Ahmad et al showed 80% idiopathic
cases in his study on hirsutism in Kashmir which correlates with our
study.65
Body mass index:
 In our study 67% of patients were above normal BMI (>25). This
is supported by Atallah et al who showed that 51% of hirsutism patients
were obese.64 As an elevated BMI increases the risk for adverse health
sequences, these patients must be followed up regularly.
Ferriman Gallway score:
In this study maximum FG score was 21 which was seen in
congenital adrenal hyperplasia. The Average FG score was 15. Most of
the patients (73%) had FG score in the range of 9 to 16. All patients were
more concerned about facial hair. Qazi Mazood Ahmad et al had seen FG
score from 10 to 34 in his study.65 Face was the most common site. Chest
and abdomen were next common sites in their study.
Nd YAG laser hair reduction:
Twenty patients, in the age group of 19 to 44 years, were randomly
selected for Nd YAG laser hair reduction. Among them, 6 patients had
PCOS.
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Skin type:
Most of  the patients  were skin type IV (50%) and V (40%).  Only
10% patients had skin type III. There is no difference in the hair removal
efficacy between skin types. This is supported by Ismail.73
Sittings:
Most  of  the  patients  responded  after  the  5th sitting. This is
statistically significant. Tahir  Kamal showed 50% good response in the
first sitting.74 They have used higher energy in the first sitting itself. But
in our study energy was started from 25% and gradually increased by 5%
for each sitting.
Hair removal efficacy:
In our study 70% patients showed good response (50 to 75% hair
reduction) and 20% patients showed excellent response (more than 75%
hair  reduction)  at  the  end  of  6th sitting. Tahir Kamal et al noted good
response in 58% cases and excellent response in 20% patients after 6
sittings with fluence. 74  This is comparable with our inference. Goldberg
et al showed 59% hair reduction.75
Efficacy in PCOS and non PCOS group:
There is no statistically significant difference in hair removal
efficacy between PCOS and non PCOS group. Further studies are needed
to confirm this finding.
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Side effects:
Q switched Nd YAG laser hair reduction resulted in transient
erythema and perifollicular edema in 90% patients which resolved
spontaneously within 6 hours. Pain was noted in 80% patients. For them
local anesthetic was used before procedure in further sittings. Crusting
occurred in 10% cases. No pigmentary disturbance or scarring was noted
in our study. No patient developed HSV infection after procedure. All
these findings are supported by Christopher et al.76  They had done laser
hair removal for 364 patients in various sites and recorded similar side
effects.
Follow up:
After 6 months, 10 patients came for follow up. Among them, one
patient had hair regrowth of 30 to 40% and 9 patients maintained their
hair reduction. Ferraro et al had noted 40 to 65% hair regrowth after hair
removal with Nd YAG laser in 480 patients during two years follow up
period.77
IPL hair removal:
Twenty  randomly  selected  patients,  in  the  age  group  of  18  to  45
years, were given IPL treatment. Among them, 11 patients had polycystic
ovarian syndrome.
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Skin type:
Most of our patients had skin type IV and V. There was no change
in  the  efficacy  of  IPL  in  the  different  skin  types.  This  is  supported  by
Ismail. 73 and Khodaeyani et al.78
Sittings:
After 4 sittings 45% of patients achieved maximum result. This
finding was confirmed by Maya.79  In her study, IPL was given for type
IV and V skin patients and maximum result was achieved after 4 sittings.
Hair removal efficacy:
In this study 70% patients showed good response (>50% hair
reduction) and 15% patients showed excellent response (>75% hair
reduction)  at  the  end  of  6  sittings.  This  feature  was  also  noted  by  Tahir
kamal et al.74 He found excellent response in 30% of cases and good
response in 62% of cases after the same period.
Efficacy in PCOS and nonPCOS groups:
There was no difference in hair reduction between PCOS patients
and non PCOS patients in this study which is also supported by Taylor et
al.80
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Satisfaction level:
In this  study,  70% of our patients  in the IPL group were satisfied
and 25% patients were very satisfied. According to Fodor et al, only 60%
patients rated their satisfaction to be good.81
Side effects:
           None of our patients showed any side effect. Similarly, Harvey jay
showed minimal side effects (temporary skin lightening or darkening  in
3 patients,  acne-like rashes in 6 patients and slight tingling sensations or
sensitivity in 2 patients) in 250 hirsutism patients.82
Follow up:
           After 6 months, 11 cases came for follow-up of which 9 patients
maintained their results and 2 patients developed regrowth of hair.
Agneta Troilium et al showed long lasting hair reduction in all cases.83
Small sample size and short follow up may be the reason why we are not
able to confirm the finding.
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CONCLUSIONS
1. Hirsutism is commonly seen in the age group of 14 to 48 years.
Adolescent patients appear to be more concerned about hirsutism
as compared to those in the older age group.
2. Acanthosis nigricans (31.5%) was the most common cutaneous
finding in our study. Acne was associated in 17.8% patients.
Androgenetic alopecia was found in 15% of cases.
3. Infertility was seen in 12.2% case. Diabetes mellitus with
hypertension was seen in 9.6% patients and obesity in 28% of
patients.
4. Idiopathic hirsutism (53%) was the most common cause in our
study. PCOS (31.5%) was the second common cause. Family
history was present in 22% cases.
5. Due to PCOS, hypothyroidism and Cushing’s syndrome, 48% of
patients had menstrual irregularities.
6. Most of the patients (73%) had Ferri Gallwey score in the range of
8 to 16. All patients, however, were more concerned about facial
hair than those on other body areas.
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7. In Q switched Nd YAG, most of the patients had good response
after the 5th sitting. In IPL, majority had good response after the 4th
sitting.
8. Good  response  was  seen  in  70%  of  the  patients  in  both  NdYAG
and IPL groups. Excellent response was seen in  20% of  Nd YAG
group and 15% of IPL group. There is no difference in hair
removal efficacy between PCOS and non PCOS patients.
9.  In  Q  switched  Nd  YAG  and  IPL  hair  removal,  there  was  no
difference in efficacy in different skin types.
10. Transient erythema, edema and crusting were the complications
observed  in  Q  switched  Nd  YAG  laser  hair  reduction.  No  side
effects with IPL laser were noted in our study.
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10 29 28 N M W N N Y N 35 N N N N N N 18 1 4 28 1 65 3 +
11 15 12 N U St N N N N 24 N N N N N N 16
12 44 25 N M W N N N N 28 N N N N N N 16 2 5 18 4 50 2 -
13 29 24 Y U W N N Y N 30 Y N N Y N N 19 2 5 26 4 52 2 -
14 15 13 N U St N N Y N 25 N N N N N N 9
15 45 38 N M HW N N N N 27 N N N Y Y N 11
16 27 19 Y M W N N N Y 25 Y N N N N N 18
17 29 23 N U W N N Y N 32 N N N N Y N 16
18 22 19 N U St N N N N 24 N N N N N N 14 1 4 12 1 65 2 +
19 23 18 N U St N N N N 22 N N N N N N 16 1 4 16 1 60 2 +
20 20 16 Y U St N N Y N 26 Y N N N N N 18 1 5 20 3 55 2 +
21 30 25 N U W N N Y N 29 N N N N N N 15 1 5 16 2 70 3 +
22 38 15 N M HW N N Y N 26 N N N N N N 9
23 42 14 N M HW N N N N 30 N N N N N N 19 2 4 18 4 50 2 -
24 41 20 N M W N N N N 28 N N N N N N 16 2 5 21 4 55 2 -
25 22 19 Y U St N N N N 25 Y N N N N N 20 2 4 24 3 60 2 -
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26 23 22 N U W N Y N N 25 N N N N N N 12 2 4 14 1 55 2 -
27 25 16 N U W N N N N 22 N N N N N N 14 2 4 12 4 58 2 -
28 22 18 N U St N N N N 20 N N N N N N 11
29 24 22 Y M HW N N N N 26 Y N N N N N 16 1 5 18 1 65 2 +
30 19 10 Y U St N N Y N 29 Y N N N N N 16 2 4 25 3 80 3 -
31 30 28 Y M HW N Y N N 28 N Y N N N N 18 1 5 24 4 50 1 +
32 22 18 N U W N Y N N 25 N N N N N N 10
33 25 22 Y M St Y N N N 26 Y N N N N N 18 2 5 22 4 60 2 -
34 20 16 N U St N N Y N 33 N N N N N N 16 2 5 18 4 60 2 -
35 22 21 Y M HW N Y Y N 20 Y Y N N N N 11 2 5 20 2 68 3 -
36 19 13 N U St N N Y N 35 N N N N N N 12 1 3 16 2 78 3 +
37 16 14 N U St N Y N N 30 N N N N N N 10
38 33 30 Y M HW N N Y Y 32 N Y N N N N 18
39 48 25 Y M HW N N N N 31 Y N N Y N N 12
40 38 33 Y M HW N N Y N 24 N Y N Y N N 14
41 40 30 N M HW N N Y N 32 N N N N N N 12
42 25 18 Y M HW N N N N 28 N N D N N N 21
43 18 12 Y U W Y N N N 27 Y N N N N N 16 1 4 22 3 76 3 -
44 45 30 N M HW N N N N 32 N N N N N N 14 1 4 18 4 45 1 +
45 42 35 Y M HW Y N N Y 33 N Y N N N N 12
46 18 14 N U St Y N N N 24 N N N N N N 11 1 4 18 2 65 3 +
47 19 14 N U St N N N N 23 N N N N N N 10 1 4 14 1 68 3 +
48 19 18 Y M HW Y N Y Y 26 Y N N N N N 13
49 33 28 Y M W N N N N 24 Y N N N N N 18 2 5 19 4 82 3 -
50 19 16 N U St Y Y N N 19 N N N N N N 12 2 3 14 1 76 3 -
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51 36 27 N M HW N N Y N 28 N N N N N Y 18 2 5 16 4 58 2 -
52 42 32 N M W N N Y Y 42 N N N Y Y Y 19
53 35 30 N M HW Y Y N N 30 N N N N Y N 14
54 25 17 Y U St N N N N 20 Y N N N N N 12 1 3 21 2 66 3 +
55 36 19 N M HW Y Y N N 23 N N N N N N 9
56 20 19 Y U St Y Y N N 24 Y N N N N N 11 1 4 18 2 76 3 -
57 18 17 Y U St N N N N 22 Y N N N N N 14 1 5 16 4 65 2 +
58 29 19 Y M W Y N N N 24 Y N N N N N 18 2 4 14 3 60 2 -
59 32 22 Y M HW N Y Y N 25 Y N N N N N 19 2 4 28 4 55 2 -
60 34 27 Y M HW Y N N N 37 Y Y N N N N 21 2 4 16 4 45 1 -
61 27 24 N U W N N N N 23 N N N N N N 18 1 5 16 3 55 2 +
62 28 25 N M HW Y N N N 31 N N N N N N 11 1 4 14 4 65 2 +
63 36 13 N M W N N N N 23 N N N N N N 13 1 5 20 1 76 3 +
64 34 21 Y M W N N N N 26 Y N N N N N 12 2 4 18 4 60 2 -
65 38 24 N M HW Y N N N 31 N N N N N N 11 2 3 21 4 58 2 -
66 22 15 N U St N N N N 21 N N N N N N 14 1 5 16 1 64 2 +
67 21 14 Y U St N N N N 24 Y N N N N N 10 2 4 22 1 75 3 -
68 18 12 N U St N N N N 26 N N N N N N 14 1 4 18 1 72 3 +
69 48 30 Y M HW N N N Y 24 Y N N N N Y 12
70 35 12 Y M HW Y N N N 26 N Y N N N N 18
71 35 14 Y M HW N N N Y 22 N N D N N N 15
72 42 32 Y M HW N N Y N 28 N Y N N Y N 17
73 46 35 Y M HW N N N Y 31 Y Y N Y Y N 14
Key to Master chart
Mens abn – Menstrual abnormalities
Marital st –  Marital status
AN –  Acanthosis nigricans
AA –  Androgenetic alopecia
BMI –  Body mass index
PCOD –  Polycystic ovarian disease
DM/HT –  Diabetes mellitus with hypertension
Lipid abn –  Lipid abnormality
FG score –  Ferriman Gallway score
Initial hair count –   No. of hairs per square cm area, done before
  the first sitting
HRE in % -  Hair removal efficiency expressed in
 percentage
Y -  Yes
N -  No
Marital status:
                        M  - Married
                        U  -  Unmarried
Occupation:
                     W – Working
                     HW – House wife
                     St – Student
Others:
C  –  Cushings syndrome
D  –  Drug induced
CAH  –  Congenital adrenal hyperplasia
Laser / IPL :
           1 – Nd YAG Laser
           2 – IPL
Skin type:
                 3 – Fitzpatrick skin type III
                 4 - Fitzpatrick skin type IV
                 5 - Fitzpatrick skin type V
Site:
        1 – Upper lip
        2 - Upper lip & chin
        3 - Upper lip, chin & sides
        4 – Chin & sides
Satisfaction:
                     1- Not satisfied
                     2- Satisfied
                     3- Very satisfied
ABBREVIATIONS
DHT - Dihydrotestosterone
DHEAS - Dehydroepiandrosterone sulphate
ACTH - Adrenocorticotropic hormone
SHBG - Sex hormone binding globulin
CAH - Congenital adrenal hyperplasia
BMI –  Body mass index
LH - Luteinizing hormone
FSH - Follicle stimulating  hormone
TSH - Thyroid stimulating hormone
GnRH - Gonadotropin releasing hormone
IGF - Insulin like growth factor
PCOS –  Polycystic ovarian syndrome
FG score  –  Ferriman Gallway score
Laser –  Light Amplification by Stimulated Emission of
Radiation
Nd YAG  –  Neodymium Yttrium Aluminium Garnet
IPL –  Intense Pulsed Light
PROFORMA
Name           :                            Age  :                           Occupation:
Address :
C/o
H/o presenting illness: H/o excessive growth of hair :
                              Duration :
                              Site :
                              Age of onset :
                              Rate of progression :
H/o voice change -
H/o loss of scalp hair -
H/o seborrhea -
H/o pimples -
H/o milky discharge from breast -
H/o wt gain -
H/o menstrual disturbances -
H/o easy fatiguability -
H/o polyuria/ polydipsia -
H/o abdominal swelling / abd pain -
H/o visual defects -
H/o neck swelling/ tremor -
H/o chest pain -
H/o drug intake -
Past h/o:
Known TB/ bronchial asthma/ hypertension/DM-
Personal h/o:
Menstrual h/o:
Age of  menarche  : Cycle :             flow :
Obstetric h/o:
Family h/o:
G/E Built -
         PR-               BP-            Ht-               Wt-            BMI
         CVS   -                             RS   -                                    P/A -
D/E      Acne vulgaris -
             Acanthosis nigricans -
             Alopecia areata -
             Moon facies -
             Buffalo hump -
             Striae -
             Hair- distribution -
Ferriman gallway score -
Genital organ & mucosa -
Palms & soles -
Nail -
Investigation:
Blood sugar -
                        Lipid profile -
                        Hormone assay- TSH   -      T3-             T4 -
                                         LH -                         FSH -
                                         Free testosterone -
                        USG abdomen   -
For  patients undergoing  Nd YAG LASER / IPL :
Sittings Energy /Fluence Hair count Side effect
Specification of Nd YAG laser
Laser type :  Q switched Nd YAG laser (Akira)
Wavelength :  1064nm & 532nm
Frequency :  Upto 5 Hz
Width of pulse :  20ns
Enegy density :  <180mj (single pulse) ; <620mj
 (direct pulse)
Spot diameter :  1-6mm
Electrical requirement :   20V / 50 HZ
Cooling System : Internal water  - to - air cooled
Dimensions (cm) : 24 x 40 x 18
Net Weight : 7 kg
Wattage :  420 w
Specification of IL – 1000
The IL – 1000 marketed by G3 laser Ltd. is the intens pulsed
light  system used in this study.
Wavelength : 400 – 1200nm
Fluence : Upto 45J
Pulse Duration :  Upto 15ms
Spot Size : 8 x 40mm
? In-built water cooling system
? Portable (Less than 20 kgs)
? Single hand Piece with minimum 6 Interchangeable filters
? Filters for HR / SR / VL / PL / AA

